Physician profile
Harold R Bailey
NPI 1386631505
$8,760.29
in general payments reported to CMS, 2019-2025
33 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,158 · 2020: $2,998 · 2021: $872 · 2022: $518 · 2023: $345 · 2024: $601 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,820.00 | 2020 | |
| Covidien LP | $1,371.60 | 2019-2020 | |
| Ethicon INC. | $910.00 | 2020 | |
| Ethicon US, LLC | $717.13 | 2019-2021 | |
| Thd America, INC. | $543.72 | 2022-2025 | |
| Pacira Pharmaceuticals Incorporated | $392.77 | 2019-2025 | Exparel |
| Allergan, INC. | $309.41 | 2019-2020 | |
| Stryker Corporation | $247.78 | 2019 | |
| Shire North American Group INC | $246.11 | 2019 | |
| Baxter Healthcare | $237.38 | 2024 | Perclot |
| Becton, Dickinson and Company | $202.24 | 2024 | Hemosphere |
| Takeda Pharmaceuticals U.S.A., INC. | $188.81 | 2020-2022 | |
| Romark Laboratories, Lc | $145.41 | 2019 | |
| Integra Lifesciences Corporation | $144.99 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.57 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $135.36 | 2019-2020 | |
| Edwards Lifesciences Corporation | $133.93 | 2019 | |
| Medtronic, INC. | $123.40 | 2023 | Signia |
| Convatec INC. | $121.10 | 2019-2022 | |
| Tela Bio, INC. | $109.72 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Boston Scientific Corporation | $106.29 | 2019 | |
| Intuitive Surgical, INC. | $99.94 | 2022 | |
| Abbvie INC. | $65.40 | 2021 | |
| Pfizer INC. | $56.69 | 2019 | |
| Merck Sharp & Dohme LLC | $31.36 | 2019-2020 | |
| Heron Therapeutics, INC. | $26.93 | 2022 | |
| Molnlycke Health Care US, LLC | $26.11 | 2019 | |
| Innovation Technologies INC | $25.81 | 2021 | |
| Baudax Bio INC. | $19.34 | 2021 | |
| Davol INC. | $17.27 | 2020 | |
| Coopersurgical, INC. | $16.88 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $16.58 | 2019 | |
| Angiodynamics, INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.